To understand the relationship between intertumoral USP14 levels and RT effectiveness in HCC patients, we performed an IHC assay to assess the immunoreactive scores (IRS) of 77 pre-treatment tumor biopsies, clinically annotated from patients scheduled for RT. The gene discussed is USP14; the disease is hepatocellular carcinoma.